Cohort study
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era
- Retrospective cohort study
- multicentre
- 15 pulmonary hypertension centres
Authors' conclusion
Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs.
Study context
- Population
- Acute vasoresponders with idiopathic, heritable or drug-induced PAH treated with initial CCB, diagnosed 1999–2018
- Participants
- 162 acute vasoresponders
- Exposure
- CCB long-term responders vs nonresponders among acute vasoresponders
- Outcome
- Long-term response to calcium channel blockers (CCBs)
- Follow-up
- 12 months after CCB initiation
Main finding
As reported in the abstract
CCB long-term response · 12 months
CCB long-term response
54.3%
Observational data: associations, not effects.
Further findings
5-year survival · up to 5 years
Overall survival during follow-up · median 60.0 months (IQR 30.8-60.0)
- Overall survival
- 86.7%
Treatment at 12 months
- CCB monotherapy
- 53.2%
- Initial CCB plus another initial PAH therapy
- 14.7%
Predictors of long-term response and survival
- Pulmonary artery compliance at testing, low risk status and NT-proBNP at early follow-up correlated with long-term response and predicted survival
Original publication
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era. Circulation. Published 12 April 2024. doi:10.1161/circulationaha.122.063821
Summarised from the published abstract; every number is checked against it